C34 C78.0
Conditions
Interventions
Group 1: SABR was performed with total doses of 35 Gy (5 fractions) or 37.5 Gy (3 fractions) prescribed to the 60% isodose line encompassing the PTV.
Three-monthly follow-up CT scans were supplemented
Sponsors
Universitätsklinikum Freiburg, Klinik für Strahlenheilkunde
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - presence of one or two FDG-PET positive pulmonary nodules /= 60% - Life expectancy > 6 months - Age > 18 years (no other age limits) - Informed consent signed in accordance with institutional protocol
Exclusion criteria
Exclusion criteria: - NSCLC: FDG-PET N+ if not ruled out by mediastinoscopy or other tissue sampling - in metastases: disseminated progressive disease without local control to be reasonably expected by current treatment - Histologically proven SCLC - More than two lesions to treat - Diameter of tumor > 5cm - Systemic therapy +/- one week of treatment - psychological/mental status does not allow informed consent and participation in QoL assessments - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local progression-free survival rates after stereotactic ablative radiotherapy (SABR) for small lung tumors at one year and two years (CT scans every 3 months or PET/CT respectively) | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, rate of toxicities | — |
Countries
Germany
Contacts
Public ContactViola Duncker-Rohr
Universtätsklinik Freiburg i. Br. Klinik für Strahlenheilkunde
Outcome results
None listed